![National Center for Cancer Immune Therapy CCIT-DK on Twitter: "Congratulations to @DoniaMarco for completing the @myESMO Leaders Generation Programme #LGP18 at #esmo18 https://t.co/xdTAOfqmbh" / Twitter National Center for Cancer Immune Therapy CCIT-DK on Twitter: "Congratulations to @DoniaMarco for completing the @myESMO Leaders Generation Programme #LGP18 at #esmo18 https://t.co/xdTAOfqmbh" / Twitter](https://pbs.twimg.com/media/Dp9ELL_WkAAqR5G.jpg:large)
National Center for Cancer Immune Therapy CCIT-DK on Twitter: "Congratulations to @DoniaMarco for completing the @myESMO Leaders Generation Programme #LGP18 at #esmo18 https://t.co/xdTAOfqmbh" / Twitter
![Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO's Vision 2025 – VHIO – Vall d'Hebron Institute of Oncology Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO's Vision 2025 – VHIO – Vall d'Hebron Institute of Oncology](https://www.vhio.net/wp-content/uploads/ESMO-1.jpg)
Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO's Vision 2025 – VHIO – Vall d'Hebron Institute of Oncology
![Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group - Annals of Oncology Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/ca1e9830-48d9-4cf9-bc3f-4f1c7528a9a7/gr1.jpg)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group - Annals of Oncology
![Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO's Vision 2025 – VHIO – Vall d'Hebron Institute of Oncology Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO's Vision 2025 – VHIO – Vall d'Hebron Institute of Oncology](https://www.vhio.net/wp-content/uploads/AnaO-1-1024x682.jpg)
Newly appointed ESMO faculty: VHIO investigators join forces with other leading experts in oncology to deliver on ESMO's Vision 2025 – VHIO – Vall d'Hebron Institute of Oncology
![ESMO: In landmark win, Novartis' Kisqali extends breast cancer survival by one year. Can it challenge Pfizer's Ibrance? | Fierce Pharma ESMO: In landmark win, Novartis' Kisqali extends breast cancer survival by one year. Can it challenge Pfizer's Ibrance? | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1631888453/KISQALI.jpg/KISQALI.jpg?VersionId=z8MNkkxR0NDWpo0UWDPq_nc48qMKO_Zb)
ESMO: In landmark win, Novartis' Kisqali extends breast cancer survival by one year. Can it challenge Pfizer's Ibrance? | Fierce Pharma
![Stream episode ESMO Leaders Generation Programme – an alumni insight by BMJ talk medicine podcast | Listen online for free on SoundCloud Stream episode ESMO Leaders Generation Programme – an alumni insight by BMJ talk medicine podcast | Listen online for free on SoundCloud](https://i1.sndcdn.com/artworks-000230606779-eifkkb-t500x500.jpg)
Stream episode ESMO Leaders Generation Programme – an alumni insight by BMJ talk medicine podcast | Listen online for free on SoundCloud
Cancer Research UK Manchester Institute - Huge congratulations to Sara Valpione, from our Molecular Oncology Group, who was selected to take part on the ESMO - European Society for Medical Oncology Leaders
![The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series - ESMO Open The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series - ESMO Open](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0ca1ee8e-770d-4a4a-bc8b-189a3908684d/gr1_lrg.jpg)